There is currently no cure for NP-C, and until recently, treatments focused only on managing symptoms. These therapies may be at least partially successful in treating some symptoms of NP-C, but have no impact on disease progression or long-term outcomes. Symptoms that can be treated with general therapies include, but are not limited to:
In January 2009, a drug (a small iminosugar) that inhibits the enzyme responsible for the first step in the synthesis of glycosphingolipids was approved in the European Union as the first treatment specifically for patients with NP-C with progressive neurological disease. In clinical studies, this drug has been shown to slow down progression of neurological symptoms.